Pricing Log in Create free account

Glass House Brands Inc. (GLAS) vs Organogenesis (ORGO)

Glass House Brands Inc. and Organogenesis are both Drug Manufacturers Specialty & Generic companies. Glass House Brands Inc. is the larger, with a market value of $172.7M against $108.1M — 1.6× the size. Glass House Brands Inc. grew revenue faster over the last twelve months: −15.4% against −24.3%. Glass House Brands Inc. has the higher net margin (−36.2% vs −43.5%) and the higher return on invested capital (−23.4% vs −52.2%). Across the 17 metrics below, Organogenesis leads on 9 and Glass House Brands Inc. on 8.

Valuation

Metric GLAS ORGO Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S 1.14 0.30 2.08
P/B 2.79 0.89 1.79
Price to free cash flow n/m 30.18 16.29
EV/EBITDA n/m n/m 12.22
EV/Sales 1.35 0.27 2.87
Earnings yield (33.33%) (145.78%) (15.94%)
Free cash flow yield (18.18%) 3.31% 0.00%

Profitability

Metric GLAS ORGO Drug Manufacturers Specialty & Generic median
Gross margin 31.97% 65.56% 53.51%
Operating margin (23.18%) (24.45%) 0.00%
Net margin (36.19%) (43.50%) (2.45%)
Free cash flow margin (20.78%) 1.01% 0.00%
Return on equity (74.02%) (81.71%) (0.80%)
Return on assets (19.78%) (34.86%) (1.67%)
Return on invested capital (23.36%) (52.15%) 0.00%

Growth

Metric GLAS ORGO Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (15.38%) (24.33%) 5.22%
EPS growth (last fiscal year) (161.90%) 1,600.00% 42.91%
Revenue growth, 5-year CAGR — 10.77% 7.24%
Net income growth, 5-year CAGR — 3.04% 0.00%

Health

Metric GLAS ORGO Drug Manufacturers Specialty & Generic median
Debt to equity 0.77 0.09 0.04
Current ratio 1.33 3.32 2.41
Net debt to EBITDA (64.84) (1.14) 1.01

Dividend

Metric GLAS ORGO Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric GLAS ORGO Drug Manufacturers Specialty & Generic median
Market cap 172.67m 108.08m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack